Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and telehealth subsidiary Lemonaid Health.

June 14, 2025•by TruthOrFake AI

✓

VERDICT

True

# Fact Check: TTAM Research Institute to Acquire 23andMe's Assets ## What We Know TTAM Research Institute, a nonprofit organization led by Anne Wojci...

Fact Check: TTAM Research Institute to Acquire 23andMe's Assets

What We Know

TTAM Research Institute, a nonprofit organization led by Anne Wojcicki, co-founder and former CEO of 23andMe, has reached an agreement to acquire substantially all of 23andMe's assets. This includes the company's Personal Genome Service and its telehealth subsidiary, Lemonaid Health, for a total of $305 million. The agreement follows a competitive bidding process approved by the U.S. Bankruptcy Court for the Eastern District of Missouri, where TTAM was selected over Regeneron Pharmaceuticals, which had previously offered $256 million for the assets (23andMe Reaches Agreement for Sale of Business to TTAM, Anne Wojcicki's nonprofit wins bid to acquire genetic).

The deal is designed to ensure compliance with 23andMe's privacy policies and includes commitments to enhance consumer protections regarding customer data. TTAM has pledged to honor existing customer rights, such as the ability to delete accounts and opt-out of research (23andMe Reaches Agreement for Sale of Business to TTAM, Anne Wojcicki to buy back 23andMe and its data for $305).

Analysis

The claim that TTAM Research Institute will acquire substantially all of 23andMe's assets, including its Personal Genome Service and Lemonaid Health, is supported by multiple credible sources. The primary announcement from 23andMe itself confirms the details of the acquisition, including the specific assets involved and the purchase price (23andMe Reaches Agreement for Sale of Business to TTAM).

Additionally, reports from major news outlets such as CNN and CNBC corroborate the details of the transaction, noting the competitive bidding process and the commitments made by TTAM regarding customer data privacy (Anne Wojcicki's nonprofit wins bid to acquire genetic, Anne Wojcicki to buy back 23andMe and its data for $305).

The reliability of these sources is high, given that they include official press releases and reputable news organizations that have covered the story extensively. The involvement of the U.S. Bankruptcy Court adds a layer of legal oversight to the transaction, ensuring that the process is conducted transparently and in accordance with applicable laws.

Conclusion

The claim that TTAM Research Institute will acquire substantially all of 23andMe's assets, including its Personal Genome Service and telehealth subsidiary Lemonaid Health, is True. This conclusion is based on multiple reliable sources confirming the details of the acquisition, including the specific assets involved and the financial terms of the deal.

Sources

Have a claim you want to verify? It's 100% Free!

Our AI-powered fact-checker analyzes claims against thousands of reliable sources and provides evidence-based verdicts in seconds. Completely free with no registration required.

💡 Try:

"Coffee helps you live longer"

✓100% Free

✓No Registration

✓Instant Results

Comments

Loading comments...

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and telehealth subsidiary Lemonaid Health.

Fact Check: TTAM Research Institute to Acquire 23andMe's Assets

What We Know

Analysis

Conclusion

Sources

Have a claim you want to verify? It's 100% Free!

Comments

Comments

Leave a comment

More Fact Checks to Explore

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

Fact Check: TTAM Research Institute will acquire substantially all of 23andMe’s assets for $305 million, including its Personal Genome Service and Research Services business lines as well as telehealth subsidiary Lemonaid Health.

Fact Check: Anne Wojcicki, the co-founder and former CEO of 23andMe, regained control of the company after her nonprofit, TTAM Research Institute, outbid Regeneron Pharmaceuticals for $305 million.

Fact Check: Regeneron Pharmaceuticals initially announced it would purchase most of 23andMe’s assets for $256 million before Wojcicki's TTAM submitted a higher bid.

Fact Check: Regeneron Pharmaceuticals initially announced a bid of $256 million for most of 23andMe’s assets before TTAM submitted a higher bid.

Fact Check: Regeneron Pharmaceuticals initially announced a bid of $256 million for most of 23andMe’s assets before Anne Wojcicki's TTAM submitted a higher bid.